EGFR Mutation Detection, Tissue/Block

What is EGFR mutation detection test?

EGFR mutation detection test analyzes a patient's tumor tissue to identify genetic mutations in the Epidermal Growth Factor Receptor (EGFR) gene, primarily for non-small cell lung cancer (NSCLC). EGFR mutation detection test helps determine if a patient's cancer is susceptible to certain tyrosine kinase inhibitor (TKI) drugs, enabling personalized treatment plans and improved patient outcomes.

Why consider EGFR mutation detection test?

EGFR mutation detection test helps oncologists choose the most effective treatment, guiding whether a patient may benefit from a TKI such as gefitinib or erlotinib, and can also detect resistance mutations.

• Guides Targeted Therapy
• Personalized Treatment
• Detects Resistance Mutations

Who should get this EGFR mutation detection test?

EGFR mutation detection test is recommended by clinicians for

• Patients primarily those with newly diagnosed non-small cell lung cancer (NSCLC), especially adenocarcinoma, to determine if their tumor has an EGFR gene mutation
• Patients with advanced NSCLC, especially adenocarcinoma or NSCLC‑NOS with adenocarcinoma features, as part of standard biomarker workup regardless of age, sex, or smoking history.
• Cases with sufficient tumor in FFPE blocks or slides; cytology cell blocks can also be suitable when tissue is limited, per lab validation.

More Information about EGFR mutation detection test

EGFR mutation refers to a change in the epidermal growth factor receptor gene that causes continuous activation of its tyrosine kinase signaling, driving tumor growth, most commonly in non‑small cell lung cancer (NSCLC). The two most common mutations are exon 19 deletions and the exon 21 L858R point mutation, together accounting for about 85–90% of EGFR mutations in NSCLC.

Other Names: EGFR Mutation Analysis, EGFR Mutation detection, EGFR gene test, EGFR Exon 18–21 Analysis; EGFR Molecular Testing on FFPE Block.